title: [Advances in superenzyme gene therapy in penile rehabilitation].
abstract: Erectile dysfunction (ED) is an almost unavoidable complication of radical prostatectomy. At present, though the concept of penile rehabilitation (PR) is accepted by most clinicians, the outcomes of erectile function recovery vary widely. Prostacyclin (PGI2) is a prostanoid and a main vasoprotectant which induces smooth muscle relaxation, but not used for replacement therapy because of its high unstability. SuperEnzyme is capable of continuous, specific and targeted promotion of PGI2 synthesis, and helps PR in ED patients after radical prostatectomy. SuperEnzyme gene therapy has a promising prospect for PR and the management of ED. This review updates SuperEnzyme gene therapy in PR.
authors.affiliation: Research Center of Regenerative Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. stinphen@163.com
authors.forename: Feng
authors.initials: F
authors.lastname: Qin
authors.forename: Wang
authors.initials: W
authors.lastname: Run
authors.forename: Jiu-Hong
authors.initials: JH
authors.lastname: Yuan
mesh_terms: D057487:Enzyme Therapy; D011464:Epoprostenol; D007172:Erectile Dysfunction / Q000534:rehabilitation / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008297:Male; D010410:Penile Erection; D010413:Penis; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism
chemical_list: D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases